Note: This story was updated March 31, 2021, to note that the ALSummit trial has been approved by the U.S. Food and Drug Administration but will proceed only in Korea; there are no plans to open additional sites in the U.S. or elsewhere. A Phase 3 clinical trial is…
“What the heck happened to that guy?” a young boy called loudly to a woman leading him and other preschool children across the parking lot. I was loading my husband, Todd, into the back of our accessible van, having just gotten our COVID-19 vaccinations. It was the first time…
“When she walks, she’s like a samba, That swings so cool and sways so gently, That when she passes, Each one she passes goes, ‘Ah.'” One day last month, if the “tall and tan and young and lovely” striking presence…
Although I was smack in the middle of a vast parking lot and surrounded by a hundred strangers, I felt genuinely hopeful for the first time in a long, long while. I was in line for my first shot of the Moderna COVID-19 vaccine, so feelings of hesitancy and…
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference, March 15–18. Go here to read the latest stories from the conference. Long-term treatment with AMX0035 significantly lowers the risk of death, and the need for permanent ventilation and hospitalization…
I gave up social media for Lent. Many Christians deny themselves some pleasure or refrain from a vice or a bad habit for a period of preparation and reflection in the weeks leading up to Easter. It seemed like a good time for me to take a break from my…
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference, March 15–18. Go here to read the latest stories from the conference. Respiratory symptoms in people with amyotrophic lateral sclerosis (ALS) significantly affect their ability to independently perform daily tasks,…
“Missed it by that much …” That was one of the catchphrases from the farcical spy situation comedy “Get Smart,” a Mel Brooks brainchild. Maxwell Smart, Agent 86, frequently uttered those…
The first patient has been enrolled in a Phase 2a clinical trial investigating Helixmith’s gene therapy Engensis (VM202) for the treatment of amyotrophic lateral sclerosis (ALS), the company announced. The REViVALS-1A study (NCT04632225) intends to recruit 18 patients across four clinical sites in the U.S. Enrollment is open…
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference, March 15–18. Go here to read the latest stories from the conference. Variants in the WWOX gene may contribute to the development of amyotrophic lateral sclerosis (ALS)…
